BEIJING, Dec. 29 (Chinese medianet) -- The Food and Drug Administration (FDA) recently approved the first drug that will help with producing longer eyelashes, according to media reports Monday.
Latisse, produced by the company of Allergan, is sup
The active ingredient in the once-daily prescription treatment is bimatroprost, the same ingredient that is in Allergan's glaucoma treatment Lumigan.
Allergan states that "Latisse users can expect to experience longer, fuller, and darker eyelashes in as little as eight weeks, with full results in 16 weeks." If Latisse is stopped, eyelashes will gradually return to their previous appearance as new eyelashes grow in.
The company also stated, "Latisse is the first and only science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes."
Allergan noted that Latisse may cause darkening of the eyelid skin, which may be reversible, and it "may also cause increased brown pigmentation of the colored part of the eye, which is likely to be permanent."
The drug is the first prescription product for lengthening eyelashes, making sales forecasting a little difficult although Allergan said it estimates global peak sales could top 500 million U.S. dollarsa year.
(Agencies)
Posts
No comments:
Post a Comment